“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in -
Last close As at 02/06/2023
-0.37
▲ −0.02 (−5.13%)
Market capitalisation
USD6m
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 2.6 | (49.4) | (82.2) |
| Relative | (8.3) | (53.6) | (81.7) |
| 52 week high/low | US$2.4/US$0.4 |
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
| Y/E Jun | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2020A | 0.0 | (9.0) | (9.0) | (172.80) | N/A | N/A |
| 2021A | 0.0 | (9.8) | (10.3) | (153.02) | N/A | N/A |
| 2022E | 1.8 | (14.6) | (14.8) | (97.62) | N/A | N/A |
| 2023E | 10.2 | (13.2) | (13.8) | (63.67) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
